LUCD Stock Summary and Trading Ideas (Lucid Diagnostics | NASDAQ:LUCD)

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Lucid Diagnostics trades on the NASDAQ stock market under the symbol LUCD.

As of April 1, 2026, LUCD stock price was flat at $1.15 with 662,469 million shares trading.

LUCD has a beta of -0.15, meaning it tends to be less sensitive to market movements. LUCD has a correlation of 0.00 to the broad based SPY ETF.

LUCD has a market cap of $195.92 million. This is considered a Micro Cap stock.

Last quarter Lucid Diagnostics reported $2 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $167,880 and missed earnings estimates by -$.02.

In the last 3 years, LUCD traded as high as $27.75 and as low as $.63.

The top ETF exchange traded funds that LUCD belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

LUCD has underperformed the market in the last year with a price return of -22.8% while the SPY ETF gained +18.5%. However, in the short term, LUCD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.5% vs -3.6% return in SPY. But in the last 2 weeks, LUCD shares have been beat by the market, returning -16.7% compared to an SPY return of -2.1%.

LUCD support price is $1.11 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LUCD shares will trade within this expected range on the day.